Clinical Trial Update: Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update of ixabepilone in patients with recurrent or persistent endometrial cancer; completed with posted results in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Adenocarcinoma
• Endometrial Carcinoma

Drugs mentioned

• Ixabepilone (ixabepilone)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2015-05-21